Company Information

  

Address: 530 FAIRVIEW AVENUE NORTH  
City: SEATTLE 
State: WA 
Zip Code: 98109 
Telephone: 206-378-6266 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

We develop, manufacture and sell robust, intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. Our nCounter Analysis System directly profiles hundreds of molecules simultaneously using a novel barcoding technology that is powerful enough for use in research, yet simple enough for use in clinical laboratories worldwide. We market our systems and related consumables to researchers in academic, government, and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of disease and to clinical laboratories and medical centers for diagnostic use. As of December 31, 2017, we had an installed base of approximately 605 nCounter systems, which our customers have used to publish more than 1,800 peer-reviewed papers.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-1.72NAN/E
12/2017-1.84NAN/E
09/2017-2.05NAN/E
06/2017-2.11NAN/E
03/2017-2.47NAN/E
12/2016-2.34NAN/E
09/2016-2.24NAN/E
06/2016-2.22NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.12Total Liab/Total Assets0.71
Net Inc/Total Assets-0.32Total Liab/Inv Cap0.96
Net Inc/Inv Cap-0.43Total Liab/Comm Equity0.27
Pretax Inc/Net Sales-0.38Interest Coverage Ratio-6.05
Net Inc/Net Sales-0.38Curr Debt/EquityNA
Cash Flow/Net Sales-0.45LTD/Equity1.22
SG&A/NetSales0.65Total Debt/Equity1.22
Asset Utilization   Liquidity  
Net Receivables Turnover5.50Quick Ratio2.84
Inventory Turnover1.88Current Ratio3.39
Inventory Day Sales0.00Net Rec/Curr Assets0.16
Net Sales/Work Cap1.34Inv/Curr Assets0.16
Net Sales/PP&E8.17  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 23.09 35.23 27.02 34.59
Cost of Goods Sold 7.70 9.19 7.31 8.22
Selling & Admin Exps 19.44 19.74 18.38 18.65
Operating Income -17.88 -7.37 -10.04 -3.31
Interest Exp 1.56 1.57 1.56 1.53
Pretax Income -19.14 -8.68 -11.36 -4.51
Other Income 0.30 0.26 0.24 0.33
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -19.20 -8.75 -11.40 -4.56

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 60.51 77.56 89.85 99.34
Receivables - Total 16.30 19.56 18.29 18.48
Inventories - Total 19.07 20.06 18.52 15.76
Total Current Assets 101.66 121.92 132.77 138.88
Net Property, Plant & Equipment 14.45 14.06 13.87 13.64
Total Assets 116.80 136.76 147.19 153.04
Liabilities        
Accounts Payable 13.31 17.23 22.44 15.38
Debt in Current Liabilities NA 0.00 0.00 0.00
Total Current Liabilities 30.92 35.92 39.59 32.89
Long-Term Debt 49.33 48.93 48.53 48.14
Total Liabilities 91.78 96.65 102.12 101.02
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -333.06 -313.10 -304.35 -292.95
Treasury Stock NA NA NA NA
Total Stockholders' Equity 25.01 40.11 45.07 52.02
Total Liabilities and Stockholders' Equity 116.80 136.76 147.19 153.04

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -17.70 -12.35 -10.34 -13.70
Net Cash Provided by Investing Activities 5.37 9.00 -2.79 -7.85
Net Cash Provided by Financing Activities 1.67 0.69 1.27 56.77

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201331.40-29.28-4.44
12/201447.59-50.04-2.80
12/201562.67-45.58-2.40
12/201686.49-47.09-2.34
12/2017114.90-43.56-1.84
Growth Rates38.31----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/189222,07385.72




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.